Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 6Neoplasm Metastasis 4Carcinoma 4Breast Neoplasms 4Neoplasms 3Melanoma 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Unspecified Childhood Solid Tumor, Protocol Specific 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Fibrosarcoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × reolysin × Clear all
NCT01619813 2023-08-04

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Completed
85 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡